Giuseppe F.
- Country
- Italy
- Department
- Oncologia Medica 1
Research Overview
- "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Avelumab Maintenance Versus Best Supportive Care After Second-Line Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma (AVESEC Trial)
Data & Insights
Has run more than one trial at 269 of 532 partner sites.
Specializations
Urothelial Cancer Research
The investigator specializes in treating advanced urothelial carcinoma and muscle-invasive bladder cancer, exploring innovative therapeutic approaches including targeted antibody treatments and immunotherapy combinations.
- HER2-expressing urothelial cancer treatments
- Novel antibody-drug conjugate therapies
- Immunotherapy combinations
Particular focus on developing treatment strategies for locally advanced and metastatic disease states.
Prostate Cancer Studies
Expertise in treating metastatic castration-resistant prostate cancer (mCRPC) with specialized focus on innovative therapeutic approaches including targeted radiotherapy and hormone therapy combinations.
- PSMA-targeted therapies
- Androgen receptor pathway treatments
- Bone metastasis management
Advanced experience in sequencing treatments for optimal patient outcomes in metastatic disease.
Advanced Cancer Therapeutics
The investigator works with novel therapeutic combinations and multimodal treatment approaches for genitourinary cancers.
- Combination immunotherapy protocols
- Targeted molecular therapies
- Radiotherapy integration
Specialized expertise in developing personalized treatment strategies for complex urological malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.